TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19236691

Group type: EXPERIMENTAL
Intervention: 10 week programme of supervised aerobic exercises (twice weekly) and individually tailored brief intervention lifestyle counselling
Number of subjects: 144

Group type: COMPARATOR
Intervention: Two hour education class on risk reduction post stroke
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Health related quality of life measures
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness measures
Number of subjects: 144
Study: 16585412

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 2 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Supplemental nocturnal oxygen for 2 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham-CPAP for 2 weeks
Number of subjects: 46
Study: 15147122

Group type: EXPERIMENTAL
Intervention: GM-CSF (300 microg) + recombinant hepatitis B vaccine (40 microg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group: recombinant hepatitis B vaccine (40 microg)
Number of subjects: 54
Study: 10917242

Group type: EXPERIMENTAL
Intervention: Intramedullary corticocancellous bone plug (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 60
Study: 8810206

Group type: EXPERIMENTAL
Intervention: Herbal eye drop preparation
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 1316076

Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg lomefloxacin (Group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin twice daily (Group II)
Number of subjects: 36
Study: 3907504

Group type: EXPERIMENTAL
Intervention: Short term diazepam prophylaxis (n = 152)
Number of subjects: 289

Group type: COMPARATOR
Intervention: No prophylaxis (n = 137)
Number of subjects: 289
Study: 2874047

Group type: EXPERIMENTAL
Intervention: Inhalation of salbutamol 0.1 mg/kg followed by inhalation of 0.25 mg of ipratropium bromide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined therapy of ipratropium bromide and salbutamol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with ipratropium bromide (two inhalations four times daily, 20 micrograms per inhalation) in combination with oral terbutaline and aerosolized salbutamol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide treatment
Number of subjects: 13
Study: 29606025

Group type: EXPERIMENTAL
Intervention: Individual dietary plan for home with pre-discharge advice and three follow-up visits (one, four, and eight weeks)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 144
Study: 28911067

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CAP-B) maintenance treatment
Number of subjects: 558

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 558
Study: 26021487

Group type: EXPERIMENTAL
Intervention: Dietary fibre intake (measured in quartiles)
Number of subjects: 15258

Group type: EXPERIMENTAL
Intervention: Cereal fibre intake
Number of subjects: 15258

Group type: EXPERIMENTAL
Intervention: Vegetable fibre intake
Number of subjects: 15258

Group type: EXPERIMENTAL
Intervention: Fruit fibre intake
Number of subjects: 15258

Group type: EXPERIMENTAL
Intervention: Total fibre intake (meta-analysis)
Number of subjects: 15258

Group type: EXPERIMENTAL
Intervention: Cereal fibre intake (meta-analysis)
Number of subjects: 15258

Group type: EXPERIMENTAL
Intervention: Fruit fibre intake (meta-analysis)
Number of subjects: 15258

Group type: EXPERIMENTAL
Intervention: Vegetable fibre intake (meta-analysis)
Number of subjects: 15258
Study: 23404297

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-carbohydrate diet (HC)
Number of subjects: 24
Study: 21554389

Group type: EXPERIMENTAL
Intervention: Steri‐Strip S
Number of subjects: 36

Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 36
Study: 18489014

Group type: COMPARATOR
Intervention: Transdermal nicotine (TN) 0 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 7 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 14 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 21 mg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN)
Number of subjects: 124
Study: 16582054

Group type: EXPERIMENTAL
Intervention: Patient preference randomised controlled trial (RCT) design
Number of subjects: 0
Study: 12687882

Group type: EXPERIMENTAL
Intervention: Ultrarapid train stimulation (UTS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional programmed electrical stimulation (PES)
Number of subjects: 104
Study: 10741368

Group type: EXPERIMENTAL
Intervention: DIP joint fusion simulation on dominant hand
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nondominant hand (control)
Number of subjects: 19
Study: 9362437

Group type: EXPERIMENTAL
Intervention: Pamidronate (120 mg, 2-hour infusion)
Number of subjects: 86
Study: 1328567

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once a day) for 8 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydralazine (5 mg/day) and Captopril (25 mg/day) for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once a day) and Nitrendipine (20 mg once a day)
Number of subjects: 0
Study: 3900591

Group type: EXPERIMENTAL
Intervention: Melphalan plus Prednisone (M.P.) X 6 monthly cycles
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Vincristine plus Melphalan plus Cyclophosphamide plus Prednisone (VMCP) X 6 monthly cycles
Number of subjects: 133

Group type: COMPARATOR
Intervention: Peptichemio, Cyclophosphamide, BCNU (third schedule)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: MP and VCMP arms
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Response (M. spike reduction greater than 75%)
Number of subjects: 133
Study: 31201808

Group type: EXPERIMENTAL
Intervention: Ice packs, Tylenol, and Toradol postoperative pain regimen
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard postoperative pain regimen
Number of subjects: 63
Study: 29169840

Group type: EXPERIMENTAL
Intervention: Alfaxalone (2 mg kg−1) with fentanyl (2 μg kg−1) for induction and alfaxalone variable rate infusion (VRI) combined with fentanyl constant rate infusion (CRI) (10 μg kg−1 hour−1) for maintenance (group AF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alfaxalone (2 mg kg−1) for induction and alfaxalone variable rate infusion (VRI) (0.15 mg kg−1 minute−1) for maintenance (group AP)
Number of subjects: 12
Study: 26422723

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 606
Study: 24063556

Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment-As-Usual
Number of subjects: 300
Study: 21256897

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo-TSST
Number of subjects: 83
Study: 19587126

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fruit and -vegetable diets (mean intake: 6.1 servings/d of fruits and vegetables, 2.7 mg/d of lutein and zeaxanthin)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Comparison group (standard diet, mean intake: 4.6 servings/d of fruits and vegetables, 2.1 mg/d of lutein and zeaxanthin)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: High intake of lutein and zeaxanthin (highest quintile, median 6.4 mg/d)
Number of subjects: 394
Study: 17893930

Group type: EXPERIMENTAL
Intervention: Structured education and counseling intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 115
Study: 15203438

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Chlormethiazole (CMZ)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both CBZ and CMZ
Number of subjects: 37
Study: 11589267

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/d
Number of subjects: 4056

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 120 mg/d
Number of subjects: 4056

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4056

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/d in women with BMI >26.4 kg/m2
Number of subjects: 4056

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 120 mg/d in women with BMI >26.4 kg/m2
Number of subjects: 4056

Group type: COMPARATOR
Intervention: Placebo in women with BMI >26.4 kg/m2
Number of subjects: 4056
Study: 9846035

Group type: EXPERIMENTAL
Intervention: Ondansetron (acute treatment)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ondansetron (chronic treatment)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (acute treatment)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (chronic treatment)
Number of subjects: 38
Study: 8595647

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2342
Study: 2760246

Group type: EXPERIMENTAL
Intervention: Antiseptic mouthrinse (Listerine Antiseptic)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 5% hydroalcohol control
Number of subjects: 83
Study: 68272

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 318

Group type: COMPARATOR
Intervention: Radiology
Number of subjects: 318
Study: 30586136

Group type: EXPERIMENTAL
Intervention: Template-guided lung nodule localization
Number of subjects: 213

Group type: COMPARATOR
Intervention: CT-guided lung nodule localization
Number of subjects: 213
Study: 28259517

Group type: EXPERIMENTAL
Intervention: Thoracic spine manipulation (TSM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham thoracic spine manipulation (sham-TSM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 61
Study: 25601483

Group type: EXPERIMENTAL
Intervention: MILE program (Center MILE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MILE program (Community MILE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parent Instruction
Number of subjects: 60
Study: 23702942

Group type: EXPERIMENTAL
Intervention: Sustained deep inspiration (5 seconds, 3 sets of 10 repetitions per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no breathing exercise)
Number of subjects: 75
Study: 22233613

Group type: EXPERIMENTAL
Intervention: Inelastic arm bandages with pressure between 20-30 mmHg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Inelastic arm bandages with pressure between 44-68 mmHg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Compression stockings (23-32 mmHg) for leg edema
Number of subjects: 78

Group type: COMPARATOR
Intervention: Inelastic bandages (53-88 mmHg) for leg edema
Number of subjects: 78
Study: 19969159

Group type: EXPERIMENTAL
Intervention: Exercise group (circuit-based rehabilitation, 12 sessions)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (social and educational classes, comparable duration)
Number of subjects: 58
Study: 17408917

Group type: EXPERIMENTAL
Intervention: Nasogastric tube feeding (TF) for 8 weeks, exclusively for 10 days and associated with meals thereafter, combined with psychotherapy, nutritional counseling, and a support group.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received only psychotherapy, nutritional counseling, and a support group.
Number of subjects: 0
Study: 15298072

Group type: EXPERIMENTAL
Intervention: GW-1000 (Sativex)
Number of subjects: 0
Study: 11721260

Group type: EXPERIMENTAL
Intervention: Early dynamic motion protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Immobilization (extension thumb spica cast for 3 weeks)
Number of subjects: 20
Study: 9337187

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of bupivacaine (TEA, Th1 to Th5)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard anti‐anginal therapy (control group)
Number of subjects: 40
Study: 7945741

Group type: EXPERIMENTAL
Intervention: Biperiden, 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bornaprine, 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 2979234

Group type: EXPERIMENTAL
Intervention: 0.125 mg kg‐1 h‐1 ranitidine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 0.25 mg kg‐1 h‐1 ranitidine
Number of subjects: 134
Study: 28960312

Group type: EXPERIMENTAL
Intervention: Immediate-release niacin (2 g) with high-fat meals containing saturated fatty acids (SFAs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Immediate-release niacin (2 g) with high-fat meals containing monounsaturated fatty acids (MUFAs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Immediate-release niacin (2 g) with high-fat meals containing MUFAs plus omega-3 long-chain polyunsaturated fatty acids (LCPUFAs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate-release niacin (2 g) with high-fat meals containing no fat
Number of subjects: 16
Study: 28386699

Group type: EXPERIMENTAL
Intervention: LSD (100 mcg orally)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: LSD (100 mcg orally) with ketanserin (40 mg orally)
Number of subjects: 25
Study: 26175218

Group type: EXPERIMENTAL
Intervention: Normal saline (1-3 ml) used for sealing the needle track (Group B)
Number of subjects: 322

Group type: COMPARATOR
Intervention: No sealing with normal saline (Group A)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Normal saline (Group B)
Number of subjects: 322
Study: 23352180

Group type: EXPERIMENTAL
Intervention: Long's manipulation (LM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Chinese Massage (TCM)
Number of subjects: 0
Study: 21290982

Group type: EXPERIMENTAL
Intervention: Oscillating/rotating power toothbrush (Oral‐B Precision Clean)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 0
Study: 18719035

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT angiography (CTA) and CT perfusion (CTP)
Number of subjects: 198
Study: 16531904

Group type: EXPERIMENTAL
Intervention: CBEX (chicken breast extract)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CBEX
Number of subjects: 8
Study: 13680085

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg methylphenidate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg methylphenidate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.60 mg/kg methylphenidate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11084468

Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 88
Study: 9187188

Group type: EXPERIMENTAL
Intervention: Pressure triggering of -0.5 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pressure triggering of -1 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flow triggering of 5/2 L/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flow triggering of 10/3 L/min
Number of subjects: 10
Study: 8068446

Group type: EXPERIMENTAL
Intervention: Clodronate (300 mg/daily for 5 days)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/daily for 5 days) after clodronate in 7 relapsing patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/daily for 5 days) in 8 newly diagnosed patients
Number of subjects: 27
Study: 3195851

Group type: EXPERIMENTAL
Intervention: CDP-choline (100 mg/kg/day for seven days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 8836

Group type: EXPERIMENTAL
Intervention: Benorylate suspension for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 0
Study: 31186120

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (14 mg, once daily)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Subcutaneous liraglutide (1.8 mg, once daily)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study: 28513068

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative treatment for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 80
Study: 26186140

Group type: EXPERIMENTAL
Intervention: Recombinant gliadins (after reduction/alkylation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural gliadins (before and after reduction/alkylation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-terminal domains of alpha- and gamma-gliadins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-terminal domains of alpha- and gamma-gliadins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disulfide bonds
Number of subjects: 0
Study: 23871794

Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (general)
Number of subjects: 31
Study: 22152592

Group type: EXPERIMENTAL
Intervention: n-BiPAP
Number of subjects: 540

Group type: COMPARATOR
Intervention: n-CPAP
Number of subjects: 540
Study: 19480610

Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster and pregabalin combination therapy
Number of subjects: 229

Group type: COMPARATOR
Intervention: 5% lidocaine medicated plaster monotherapy
Number of subjects: 229

Group type: COMPARATOR
Intervention: Pregabalin monotherapy
Number of subjects: 229

Group type: COMPARATOR
Intervention: 5% lidocaine medicated plaster with continued pregabalin treatment
Number of subjects: 229
Study: 16502855

Group type: EXPERIMENTAL
Intervention: Modified Japanese PHCS
Number of subjects: 1910
Study: 14642015

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: COMPARATOR
Intervention: Normal comparisons
Number of subjects: 109
Study: 10668716

Group type: EXPERIMENTAL
Intervention: IFNbeta-1a (12 mIU, subcutaneously three times a week for 6 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (subcutaneously three times a week for 6 months)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: IFNbeta-1a
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 7726317

Group type: EXPERIMENTAL
Intervention: Fluphenazine 10 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluphenazine 20 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluphenazine 30 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluphenazine (all doses)
Number of subjects: 72
Study: 2248067

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 20
Study: 7262795

Group type: EXPERIMENTAL
Intervention: Daily interval therapy (alternating application of Jellin ointment or cream and their bases, n = 26)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Conventional therapy (application of Jellin ointment or cream alone, n = 24)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Weekly interval therapy (application of Jellin ointment or cream for 4 days followed by 3 days of the corresponding base, n = 21)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Daily interval therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Interval therapy
Number of subjects: 71
Study: 31710983

Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 320

Group type: COMPARATOR
Intervention: Algorithmically generated music
Number of subjects: 320
Study: 30845322

Group type: EXPERIMENTAL
Intervention: Typhoid conjugate vaccine campaign
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Community engagement activities (meetings, media outreach, community-based activities)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Focus group discussions (FGD) with trial staff and community members
Number of subjects: 200
Study: 28135140

Group type: EXPERIMENTAL
Intervention: Previsit individualized communication coaching session with a question prompt list (QPL)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 170
Study: 26173731

Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 23958808

Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rMenB
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4CMenB (control group)
Number of subjects: 60
Study: 21252735

Group type: EXPERIMENTAL
Intervention: Trocar-guided tension-free vaginal mesh insertion
Number of subjects: 190

Group type: COMPARATOR
Intervention: Conventional vaginal prolapse surgery
Number of subjects: 190
Study: 19097910

Group type: EXPERIMENTAL
Intervention: Cemented femoral component
Number of subjects: 41

Group type: COMPARATOR
Intervention: Uncemented femoral component
Number of subjects: 41
Study: 17426211

Group type: EXPERIMENTAL
Intervention: Aid modality (small wheeled cart for oxygen canister)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-Aid modality (carried on shoulder)
Number of subjects: 60
Study: 15327808

Group type: EXPERIMENTAL
Intervention: Chronic pain with high pain-related disability
Number of subjects: 17543

Group type: COMPARATOR
Intervention: Chronic pain with no or limited pain-related disability
Number of subjects: 17543
Study: 11803600

Group type: EXPERIMENTAL
Intervention: Cobalt 60
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 15 MeV photons
Number of subjects: 40
Study: 9923411

Group type: EXPERIMENTAL
Intervention: 25 microg/kg rhIL-11
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 50 microg/kg rhIL-11
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rhIL-11 (both doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rhIL-11
Number of subjects: 80
Study: 9243145

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 54